 | ||||||
| lung cancer | ||||||
| 网页 | ||||||
| Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer Hence, we speculate that the disease-free survival of the two treatment groups in ADJUVANT could remain significantly different beyond 36 months if treatment with gefitinib was extended, analogous to the long-term use of imatinib and tamoxifen in gastrointestinal stromal tumours and breast cancer, ...
| ||||||
| 查看更多结果 | 修改此快讯 | ||||||
| 您收到此电子邮件是因为您订阅了Google快讯。 |
 以RSS Feed的形式接收此快讯 |
| 发送反馈 |
No comments:
Post a Comment